The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Seems to me that we have a lot to be grateful for this past 10 days. After the highs of the covid era and then the inevitable crash we now have good reason to believe the turn around has been succesful as the company smartly transfroms into a CDMO - avoiding biotech R&D risk and with OXB now with a lot of visibility on future earnings based on order book. We have had our first upgrade this week from Investec to BUY with a PT of 366 and more upgrades should be coming. And we have clearly seen existing institutional investors top up and some new ones take a position with volumes last week more than double the norm and on one day triple. (we were blessed that several other institutions which wanted out like Fidelity selling off 4m shares in Feb and March - did so before the strong results last Monday and so most sellers had been cleared out). We are now settling down to a new consolidation with 316 the floor/support and 347 the resistance. I dont expect that to change much over the next quarter unless a) a big institution looks to build a big stake b) we see a big deal announced which is quite possible or c) we get an offer which is unlikely. I expect we trade in this band until the interim results on September 18th and then I see 4,20
I do agree. Only one tree shake yesterday so far. Plenty of buying when it dropped.
400p and who knows if there is big news or M&A then>>>>>>>>>>
Interesting, if not all the clear to someone that doesn't often read charts.
The price is ignoring it, at this point, but plenty of time for a drop down of course.
I presonally can't see sub £2.95 from here in any pullback. Similar to RR on it's heady rise.
In an uptrend, the lower band can head in any direction, with the exception, of the higher Bollinger band, which generally heads upward. The lower band will tend to go in the same direction as the upper bollinger band, except when volatility and faster upward sp movement happens. It so happens previous fast sp, rise,was sufficient to cause the lower bollinger band to fall. Retracement measurements, are usually Fibonacci, with 38.2% to 50% of the previous bottom to top price difference used. DYOR.
What do you mean here.
Losing downward momentum is good no?
I do think retracement is likely soon anyway
“volatility based Bollinger lower band, is losing downward momentum, signalling probability that price retracement”
Sp, is churning in price range of last few days, and volatility based Bollinger lower band, is losing downward momentum, signalling probability that price retracement, is soon. Previous congestion levels, imply potential retracement between 187-300. A healthy equity can be expected to retrace between 38.2% to 50%, of an advance. Next sp, target, is 400. DYOR.
Nice.
Another strong start to the week. Long may it continue.
Certainly seems to have had its vitamins as the SP is really perky now. This was £14 at one point and still a long way to go but the rise is really promising. Not often a share recovers after such a strong decline but you can see the company has real prospects now. It is the realising of this potential that will determine us seeing £10 plus again.
I'm still here enjoying the ride though am still 50% down so want it to keep climbing!
There certainly seems a different vibe to it with the relatively new management and plan so long may it continue.
Unfortunately none of my other biotechs are even showing these promising signs so they are still in the doldrums.
Could keep on climbing.
At this rate, they might be forced to do a speeding ticket, even though it was well underpriced prior.
Broken and looks like blue skies now as little resistance.
This it the RNS for me, that was a game changer just prior to the results.
Even RR had to start its recovery somewhere...
https://www.lse.co.uk/rns/OXB/update-on-cdmo-services-kkuod0ei8hi7occ.html
20 Mar 2024 07:00
RNS Number : 4894H
Oxford Biomedica PLC
20 March 2024
Oxford Biomedica Provides Update on CDMO Services Including New Commercial Agreement
- New and expanded contracts highlight commercial momentum across all viral vector types
- OXB now working on multiple late-stage programmes with its portfolio of client programmes progressing to later stage work
Oxford, UK - 20, March, 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "OXB" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today provides an update on its CDMO services activity.
Year to date, Oxford Biomedica has experienced consistently strong demand for its CDMO services across all key viral vector types, with its portfolio of client programmes transitioning towards later stage work. As a result of commercial developments set out below, OXB is now working on three late-stage programmes.
Recently, the Company signed a contract with a new undisclosed US-based biotechnology company for the manufacture of lentiviral vectors as the client prepares for the commercial launch of its CAR-T programme targeting multiple myeloma. Manufacturing will take place in Oxbox, the Company's Oxford-based manufacturing facility.
Alongside this, Oxford Biomedica has signed two new programmes with existing clinical-stage clients for projects including Process Development and GMP manufacturing.
Furthermore, the Company has signed a new agreement with a US-based client specialising in cardiac gene therapy for the tech transfer, optimisation and manufacture of an adeno-associated virus-based process (AAV).
Under the terms of these agreements, Oxford Biomedica will receive payments related to the development and manufacturing of viral vectors for use in clinical trials in addition to certain development and regulatory milestone payments. These payments will support the Company in achieving its medium-term financial guidance announced on 5 March 2024.
Dr Sébastien Ribault, Chief Commercial Officer of Oxford Biomedica, commented: "The signing of a late-stage programme, alongside the continued expansion of existing agreements since the start of 2024, demonstrates clients' confidence in OXB's ability to deliver process development and GMP manufacturing services. Our Business Development team continues to experience strong demand for process characterisation, validation, and process performance qualification (PPQ) work, showcasing the high quality and reliability of our services. This demand is in line with our forecasts across all key vectors and geographies, validating our growth strategy. We remain confident about our future prospects as the leading global pure-play CDMO in cell and gene therapy and our ability to continue building our c
Thanks. I do look at ADFN daily as well.
Try ADVFN…Plenty of chat over there. Not sure whether this board is perhaps still in a state of shock after the horrendous past couple of years.
After a 50% rise this month -- will be interesting to see.
So quiet on this BB. Seems a lot of invididual investors are not following this one.
ABL Europe could be buying shares of course
https://www.globenewswire.com/en/news-release/2024/01/29/2818732/0/en/Oxford-Biomedica-completes-acquisition-of-ABL-Europe.html
Off we go again, another late rise
The small breakout has now solidified and the results taken well. Been a good few days for me - for a change!
Added up.
1515p to such a drop is unjustified.
Overhead supply from previous trading at 241.5. The sp, at 250, is above the resistance level, of 241.5, thus reversing the resistance level to become support. The only obvious remaining overhead supply area, is at 300, so that is the projected price target for profit. The underlying sector is bullish, providing general support to OXB. DYOR.
Et voila! *** Takes a bow ****